As filed with the U.S. Securities and Exchange Commission on August 29, 2014
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM F-6
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
For Depositary Shares Evidenced by American Depositary Receipts
___________________
Ablynx NV
(Exact name of issuer of deposited securities as specified in its charter)
n/a
(Translation of issuer's name into English)
Belgium
(Jurisdiction of incorporation or organization of issuer)
JPMORGAN CHASE BANK, N.A.
(Exact name of depositary as specified in its charter)
1 Chase Manhattan Plaza, Floor 58, New York, NY, 10005-1401
Telephone (800) 990-1135
(Address, including zip code, and telephone number, including area code, of depositary's principal executive offices)
____________________
Depositary Management Corporation
570 Lexington Avenue, 44th Floor
New York, New York 10022
(212) 319 4800
(Address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Scott A. Ziegler, Esq. | Edward A. Bibko |
Ziegler, Ziegler & Associates LLP 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 | Baker & McKenzie LLP 100 New Bridge Street London EC4V 6JA United Kingdom +44 20 7919 1000 |
It is proposed that this filing become effective under Rule 466
o | immediately upon filing | ||
o | on (Date) at (Time) |
If a separate registration statement has been filed to register the deposited shares, check the following box. o
CALCULATION OF REGISTRATION FEE
Title of each class of Securities to be registered | Amount to be registered | Proposed maximum aggregate price per unit (1) | Proposed maximum aggregate offering price (2) | Amount of registration fee |
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing one ordinary share of Ablynx NV | 50,000,000 American Depositary Shares | $0.05 | $2,500,000 | $322 |
(1) | Each unit represents one American Depositary Share. |
(2) | Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Receipts evidencing American Depositary Shares. |
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
PART I
INFORMATION REQUIRED IN PROSPECTUS
The Prospectus consists of the proposed form of American Depositary Receipt (“ADR” or “American Depositary Receipt”) included as Exhibit A to the Deposit Agreement filed as Exhibit (a) to this Registration Statement, which is incorporated herein by reference.
CROSS REFERENCE SHEET
Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED
Location in Form of American Depositary | ||||
Item Number and Caption | Receipt Filed Herewith as Prospectus | |||
(1) | Name and address of Depositary | Introductory paragraph and bottom of face of American Depositary Receipt | ||
(2) | Title of American Depositary Receipts and identity of deposited securities | Face of American Depositary Receipt, top center | ||
Terms of Deposit: | ||||
(i) | Amount of deposited securities represented by one unit of American Depositary Shares | Face of American Depositary Receipt, upper right corner | ||
(ii) | Procedure for voting, if any, the deposited securities | Paragraph (12) | ||
(iii) | Collection and distribution of dividends | Paragraphs (4), (5), (7), (10) and (11) | ||
(iv) | Transmission of notices, reports and proxy soliciting material | Paragraphs (3), (8), (11) and (12) | ||
(v) | Sale or exercise of rights | Paragraphs (4), (5), (10) and (11) | ||
(vi) | Deposit or sale of securities resulting from dividends, splits or plans of reorganization | Paragraphs (4), (5), (10) and (13) | ||
(vii) | Amendment, extension or termination of the Deposit Agreement | Paragraphs (16) and (17) | ||
(viii) | Rights of holders of ADRs to inspect the transfer books of the Depositary and the list of Holders of ADRs | Paragraph (3) | ||
(ix) | Restrictions upon the right to deposit or withdraw the underlying securities | Paragraphs (1), (2), (4), and (5) | ||
(x) | Limitation upon the liability of the Depositary | Paragraph (14) | ||
(3) | Fees and Charges | Paragraph (7) |
Item 2. AVAILABLE INFORMATION
Location in Form of American Depositary | |||
Item Number and Caption | Receipt Filed Herewith as Prospectus | ||
(a) Statement that Ablynx NV publishes information in English required to maintain the exemption from registration under Rule 12g3-2(b) under the Securities Exchange Act of 1934 on its Internet Web site (http://www.ablynx.com/) or through an electronic information delivery system generally available to the public in its primary trading market. | Paragraph (8) |
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 3. EXHIBITS
(a) | Form of Deposit Agreement. Form of Deposit Agreement dated as of , 2014 among Ablynx NV, JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all holders from time to time of ADRs issued thereunder (the "Deposit Agreement"), including the Form of American Depositary Receipt, is filed herewith as Exhibit (a). |
(b) | Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. Not Applicable. |
(c) | Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. Not Applicable. |
(d) | Opinion of Ziegler, Ziegler & Associates LLP, counsel to the Depositary, as to the legality of the securities being registered. Filed herewith as Exhibit (d). |
(e) | Certification under Rule 466. Not applicable. |
Item 4. UNDERTAKINGS
(a) | The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the American Depositary Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer. |
(b) | If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an American Depositary Receipt thirty days before any change in the fee schedule. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, JPMorgan Chase Bank, N.A. on behalf of the legal entity created by the Deposit Agreement, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The City of New York, State of New York, on August 27, 2014.
Legal entity created by the form of Deposit Agreement for the issuance of ADRs evidencing American Depositary Shares | |||
By: | JPMORGAN CHASE BANK, N.A., as Depositary | ||
By: | /s/ Gregory A. Levendis | ||
Name: | Gregory A. Levendis | ||
Title: | Executive Director | ||
Pursuant to the requirements of the Securities Act of 1933, Ablynx NV certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, on August 27, 2014.
Ablynx NV | |||
By: | /s/ Edwin Moses | ||
Name: | Edwin Moses | ||
Title: | Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Edwin Moses and Wim Ottevaere, permanent representative of Woconsult bvba, individually, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute, may lawfully do or cause to be done by virtue hereof.
Under the requirements of the Securities Act, this Registration Statement has been signed by the following persons on August 27, 2014, in the capacities indicated.
Signature | Title | |
/s/ Peter Fellner | Chairman of the Board of Directors | |
Name: Peter Fellner | ||
/s/ Edwin Moses | Chief Executive Officer and Director | |
Name: Edwin Moses | ||
/s/ Russell G. Greig | Director | |
Name: Russell G. Greig Permanent representative of Greig Biotechnology Global Consulting Inc. | ||
/s/ Bo Jesper Hansen | Director | |
Name: Bo Jesper Hansen Permanent representative of Orfacare Consulting GmbH | ||
/s/ William Jenkins | Director | |
Name: William Jenkins Principal of William Jenkins Pharma Consulting | ||
/s/ Catherine Moukheibir | Director | |
Name: Catherine Moukheibir | ||
/s/ Remi Vermeiren | Director | |
Name: Remi Vermeiren |
/s/ Wim Ottevaere | Chief Financial Officer | |
Name: Wim Ottevaere the permanent representative of Woconsult bvba | ||
/s/ Kim Simonsen | Chief Operations Officer | |
Name: Kim Simonsen | ||
/s/ Dominique Tersago | Chief Medical Officer | |
Name: Dominique Tersago | ||
/s/ Antonin de Fougerolles | Chief Scientific Officer | |
Name: Antonin de Fougerolles | ||
/s/ Guido Gielen | VP Human Resources | |
Name: Guido Gielen | ||
/s/ Gerrit Franciscus Landolt | VP IP and Legal | |
Name: Gerrit Franciscus Landolt |
SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT
Under the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Ablynx NV, has signed this Registration Statement on August 27, 2014.
DEPOSITARY MANAGEMENTCORPORATION as Authorized U.S.Representative | |||
By: | /s/ George Boychuk | ||
Name: | George Boychuk | ||
Title: | Managing Director, Depositary Management Corporation | ||
INDEX TO EXHIBITS
Exhibit Number | ||
(a) | Form of Deposit Agreement. | |
(d) | Opinion of Ziegler, Ziegler & Associates LLP, counsel to the Depositary, as to the legality of the securities to be registered. |